文献速递甲状腺疾病

双盲、安慰剂对照、随机试验:硒在Graves甲状腺功能亢进症中的作用

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项双盲、安慰剂对照、随机试验纳入70例未经治疗的Graves病甲状腺功能亢进患者,在甲巯咪唑基础上加用硒酸钠300微克/日或安慰剂24周。第24周缓解率硒组80%对安慰剂组82%(OR 0.93,95%CI 0.26-3.25,P=0.904),随访12周复发率48%对44%(OR 1.13,95%CI 0.29-2.66,P=0.81),补硒未影响缓解率或复发率。

要点

  • 在甲巯咪唑基础上加用硒酸钠300微克/日24周,未改善Graves病缓解率或复发率。
  • 第24周缓解率硒组80%对安慰剂组82%,OR 0.93(95%CI 0.26-3.25),无显著差异。
  • 随访12周复发率硒组48%对安慰剂组44%,OR 1.13(95%CI 0.29-2.66),无显著差异。

核心结论

  • 补充硒未影响Graves病的缓解率或复发率。

研究设计与样本

  • 双盲、安慰剂对照、随机补充试验,纳入70例未经治疗的Graves病甲状腺功能亢进患者。

主要发现

  • 第24周缓解率硒组25/31(80%)对安慰剂组27/33(82%),OR 0.93(95%CI 0.26-3.25,P=0.904)。
  • 12周随访期间复发率硒组11/23(48%)对安慰剂组12/27(44%),OR 1.13(95%CI 0.29-2.66,P=0.81)。
  • 第36周仍缓解者硒组12/29(41%)对安慰剂组15/33(45%),OR 0.85(95%CI 0.31-2.32,P=0.80)。
  • 血清硒和硒蛋白P浓度与缓解或复发率无关。
  • 不良反应事件硒组56例次对安慰剂组63例次(P=0.164),安慰剂+甲巯咪唑组35例中仅1例(2.9%)药物相关副作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). OBJECTIVE: Evaluate efficacy of add-on Se on medical treatment in GD. DESIGN: Double-blind, placebo-controlled, randomized supplementation trial. SETTING: Academic endocrine outpatient clinic. PATIENTS: Seventy untreated hyperthyroid patients with GD. INTERVENTION: Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. MAIN OUTCOME MEASURES: Response rate (week 24), recurrence rate (week 36), and safety. RESULTS: A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) at week 24 [odds ratio (OR) 0.93; 95% confidence interval (CI), 0.26 to 3.25; P = 0.904] in the Se (+MMI) and placebo (+MMI) groups, respectively. During a 12-week follow-up, 11 of 23 (48%) and 12 of 27 (44%) relapsed (OR 1.13; 95% CI, 0.29 to 2.66; P = 0.81) in the Se and placebo groups, respectively. Serum concentrations of Se and selenoprotein P were unrelated to response or recurrence rates. At week 36, 12 of 29 (41%) and 15 of 33 (45%) were responders and still in remission in the Se and placebo groups, respectively (OR 0.85; 95% CI, 0.31 to 2.32; P = 0.80). Serum levels of free triiodothyronine/free tetraiodothyronine, thyroid-stimulating hormone receptor antibody, prevalence of moderate to severe Graves orbitopathy, thyroid volume, and MMI starting dose were significantly lower in responders than in nonresponders. A total of 56 and 63 adverse events occurred in the Se and placebo groups, respectively (P = 0.164), whereas only one drug-related side effect (2.9%) was noted in 35 patients on placebo + MMI. CONCLUSIONS: Supplemental Se did not affect response or recurrence rates in GD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kahaly GJ, Riedl M, König J, et al. Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism. J Clin Endocrinol Metab. 2017. PMID: 29092078. doi:10.1210/jc.2017-01736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。